CAS number: 129453-61-8

General information about the Fulvestrant active pharmaceutical ingredient

Fulvestrant as active pharmaceutical ingredient (API) is an estradiol derivative, estrogen receptor antagonist used to treat breast cancer. Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. Fulvestrant is administered as an intramuscular injection.

Axplora manufactures Fulvestrant API

Fulvestrant API is manufactured in cGMP by Axplora via chemical synthesis from early stage starting material. Fulvestrant API is produced by Farmabios, our EUGMP, USFDA and PMDA approved manufacturing site with legal seat in Gropello Cairoli, Italy. Farmabios’ expertise is to make and handle with steroids, niche hormones, and highly potent active pharmaceutical ingredient (HPAPI), including cytotoxic drugs. Fulvestrant API is commercially available as fine powder and as standard grade specifically designed around various formulation requirements. Tailor-made packaging solutions are available upon request. Feel free to contact us if you need any additional information about Fulvestrant API.
  • Therapeutic area Anti-Cancer
  • Monograph PH.EUR.
  • Available grade Standard
  • Regulatory documentation US DMF#
  • Produced in GRO